title: Symptomatic pulmonary complications from liquid acrylate embolization of brain arteriovenous malformations.
abstract: OBJECTIVE
  To describe symptomatic pulmonary emboli from brain arteriovenous malformation embolization with liquid acrylates and to analyze the reasons for these complications and describe preventive techniques.
  
  
  METHODS
  The clinical records of 182 patients embolized with acrylate glue since 1978 for treatment of brain AVMs were searched for evidence of symptomatic pulmonary complications. Originally iso-butyl-2-cyanoacrylate and more recently n-butyl-2-cyanoacrylate were used in all patients. Arteriovenous malformation morphology, amounts and techniques of glue injection, and clinical and radiologic investigations in the symptomatic patients were recorded.
  
  
  RESULTS
  Three patients had pulmonary symptoms within 48 hours of glue injection. One patient with a left frontal arteriovenous malformation had embolization with an isobutyl-2-cyanoacrylate/pantopaque/acetic acid mixture; severe pleuritic chest pain developed 2 days later. One patient with a left temporal and one with a left cerebellar arteriovenous malformation had embolization with n-butyl-2-cyanoacrylate/lipiodol mixtures; a cough, pleuritic chest pain, and bloody sputum developed in both within 24 hours. Two patients experienced a significant drop in PO2. No flow-arrest techniques were used for any of the injections in these three patients. All patients demonstrated significant changes on chest x-ray and CT chest examinations. All were treated conservatively and recovered spontaneously.
  
  
  CONCLUSIONS
  Symptomatic pulmonary complications can occur after acrylate glue injection, particularly when delivery systems without flow arrest are used in high-flow vascular brain lesions. Techniques using acetic acid to delay polymerization time and "sandwich" techniques in which glue is pushed with dextrose are also more susceptible to this complication.
authors.affiliation: Department of Diagnostic Radiology, University Hospital, University of Western Ontario, Canada.
authors.forename: D M
authors.initials: DM
authors.lastname: Pelz
authors.forename: S P
authors.initials: SP
authors.lastname: Lownie
authors.forename: A J
authors.initials: AJ
authors.lastname: Fox
authors.forename: L C
authors.initials: LC
authors.lastname: Hutton
mesh_terms: D000085:Acetates / Q000008:administration & dosage; D000328:Adult; D002015:Bucrylate / Q000008:administration & dosage / Q000009:adverse effects; D002531:Cerebellum / Q000098:blood supply; D002637:Chest Pain / Q000209:etiology; D004621:Embolization, Therapeutic / Q000009:adverse effects* / Q000379:methods; D004659:Enbucrilate / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives; D005260:Female; D005947:Glucose / Q000008:administration & dosage; D006801:Humans; D007269:Injections, Intra-Arterial; D002538:Intracranial Arteriovenous Malformations / Q000628:therapy*; D007459:Iodized Oil / Q000008:administration & dosage; D008297:Male; D010100:Oxygen / Q000097:blood; D010998:Pleurisy / Q000209:etiology; D011655:Pulmonary Embolism / Q000000981:diagnostic imaging / Q000209:etiology*; D011859:Radiography; D014014:Tissue Adhesives / Q000009:adverse effects
chemical_list: D000085:Acetates; D014014:Tissue Adhesives; D002015:Bucrylate; D007459:Iodized Oil; D004659:Enbucrilate; D005947:Glucose; D010100:Oxygen